System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ahead of print

PubMed: 42268236 DOI: 10.1128/aac.00263-26

Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review.

Antimicrob Agents Chemother

Authors: Cornelia Lass-Flörl, Stephan Steixner, Angelika Bauer, Jacques F Meis, Arnaldo L Colombo, Oliver A Cornely, Arunaloke Chakrabarti, Ferry Hagen, Amanda Ribeiro Dos Santos, Amir Seyedmousavi, Shivaprakash M Rudramurthy, Roya Vahedi-Shahandashti

Affiliations

  • Institute of Hygiene and Medical Microbiology, ECMM Excellence Diamond Centre of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.
  • Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, the Netherlands.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) and Excellence Center for Medical Mycology, University of Cologne, Cologne, Germany.
  • Antimicrobial Resistance Institute of São Paulo (ARIES), Federal University of São Paulo, São Paulo, Brazil.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKSKöln), University of Cologne, Cologne, Germany.
  • Doodhadhari Burfani Hospital and Research Institute, Haridwar, India.
  • Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
  • Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
  • Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, , Chandigarh, India.

Abstract

Accurate interpretation of antifungal minimum inhibitory concentrations (MICs) requires distinguishing species-level intrinsic phenotypes from isolate-level acquired resistance. Many fungi exhibit intrinsic reduced susceptibility (IRS) reflected by wild-type (WT) MIC distributions that are shifted toward higher values (uniformly or with a high-MIC tail). This may lead to the misclassification of high-end WT isolates as resistant and compromise surveillance and cross-center comparability, particularly for rare fungi lacking established breakpoints. In this review, we propose a pragmatic and standardized framework to distinguish intrinsic phenotypes (normal susceptibility, IRS, intrinsic resistance) from acquired resistance based on species-specific WT MIC distributions and standardized WT/non-wild-type (NWT) reporting. This framework is specifically intended to guide interpretation in data-limited settings where WT distributions and epidemiological cut-off values (ECOFFs) are not yet established. MICs within the unimodal species-specific WT range, even if high, should be interpreted as potentially reflecting IRS and not as acquired resistance. Only MICs clearly right-shifted beyond the WT range should be classified as NWT by epidemiological cut-off values or, if unavailable, as putative NWT, and considered candidates for acquired resistance. When breakpoints are lacking, WT versus NWT reporting with explicit comments on IRS/intrinsic resistance is preferable to forced susceptible/resistant (S/R) categorization. In the absence of established WT distributions or ECOFFs, such classification remains provisional and should rely on descriptive MIC patterns, available data sets, and clinical context. Integrating these biological interpretations with pharmacokinetics/pharmacodynamics and clinical context supports optimized dosing, avoids inappropriate drug exclusion, and enables consistent surveillance and multicenter comparisons.

MeSH

Phenotype, Classification, Drug Therapy, Fungi, Antiviral Agents